Brought to you by 
MediGene acquires NeuroVir Therapeutics in stock swap
Nov 2000
Executive Summary
MediGene (cardiac therapeutics and cancer vaccines) has acquired cancer therapeutics company NeuroVir Therapeutics in a stock swap. MediGene has issued about 997k new shares in exchange for the 91% of the company it did not own.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MediGene acquires NeuroVir Therapeutics in stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice